Medicure Announces Full Patient Enrollment in MATCHED Clinical Trial

Medicure, a cardiovascular drug discovery and development company, has reached full enrollment in its 120-patient advanced Phase II MATCHED trial evaluating MC-4232, in patients with co-existing diabetes and hypertension.

The results of the study are expected to be announced in the summer of 2005. Patients with co-existing diabetes and hypertension face a major increase in risk of cardiovascular complications, including heart attacks, stroke, heart failure and renal failure.

MC-4232 is a novel product that combines the cardioprotective properties of Medicure's lead product, MC-1, with an ACE inhibitor, an established first line therapy for blood pressure control.